Oncology - Breast Cancer | |
|---|---|
| Study Name | Principal Investigator |
| EA1181 (CompassHER2-pCR) – A de-escalation study assessing the effect of decreasing chemotherapy in patients with HER2 positive breast cancer, with no evidence of cancer remaining after pre-operative chemotherapy and HER2-targeted therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| A191901 GETSET Study – An Additional Support Program Via Text Messaging and Telephone-Based Counselling for Breast Cancer Patients Receiving Hormonal Therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| S1501 – Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| NRG-BR007 – A De-Escalation of Breast Radiation Trial for Hormone Sensitive, Her2 Negative, Oncotype Recurrence Score less than or equal 18 Breast cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Raimonda Goldman, MD |
| A011801 – A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib”. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| NRG-BR009 – A Phase II Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0 - 1, ER Positive / HER2 Negative Breast Cancer and an Oncotype Score of 25 or less. To inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
Oncology - Colorectal Cancer | |
| Study Name | Principal Investigator |
| The JANUS RECTAL Cancer Trial – A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Lung Cancer | |
| Study Name | Principal Investigator |
| MRTX849-007 – Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advance Non-Small Cell Lung Cancer with KRAS G12C Mutation. To inquire about eligibility, please contact the Oncology research program at 201-530-7934.
Read more. |
Yadyra Rivera, MD |
Oncology - Pancreatic Cancer | |
| Study Name | Principal Investigator |
| A021806 – Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer. To inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
George Miller, MD |
Oncology - Skin Cancer | |
| Study Name | Principal Investigator |
| Alpha Tau CTP-SCC-03 – A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Benjamin Rosenbluth, MD |
